Document is current

Article History

Received: 6 May 2024

Accepted: 9 September 2024

First Online: 1 October 2024

Declarations

:

: S.L. is supported by a grant from the Alzheimer’s Association (AARF-22–920754). Y.S. reports grants from The Alzheimer’s Association, The BrightFocus Foundation, NIH/NIA, State of Arizona, outside the submitted work. C.V.-C. reports grants from the Alzheimer’s Association (AARF 2019A005859) and the National Institute on Aging (K99AG073452). J.J.P. was supported by the Arizona Department of Health Services (CTR057001). K.S.K. is on the Board of Directors for the Tau Consortium, receives funding from the NIA, the Alzheimer Association, and the Alzheimer’s Drug Discovery Foundation. P.N.T. reports receiving consulting fees from AbbVie, AC Immune, Acadia, Athira, Axsome, Biogen, BioXcel, Corium, Cortexyme, CuraSen, Eisai, Genentech, Immunobrain, Lundbeck, Novo Nordisk, Otsuka & Astex, Merck & Co., Novo Nordisk, Syneos, and T3D Therapeutics. E.M.R. and P.N.T. report grants from National Institute on Aging (P30 AG072980, R01 AG069453, R01 AG055444), Banner Alzheimer’s Foundation and the NOMIS Foundation during the conduct of the study. E.M.R. is a compensated scientific advisor for Alzheon, Aural Analytics, Denali, Retromer Therapeutics, and Vaxxinity, an uncompensated scientific advisor for Lilly, and a cofounder, advisor and shareholder of AlzPATH, which is involved in the development of blood-based biomarkers for Alzheimer’s disease outside the scope of the submitted. In addition, E.M.R. is the inventor of a patent issued to Banner Health, which involves the use of biomarker endpoints in at-risk persons to accelerate the evaluation of Alzheimer’s disease prevention therapies and is outside the submitted work. F.L. was supported by an Anonymous Foundation, and the Administrative Department of Science, Technology and Innovation (Colciencias Colombia;111565741185). E.M.R., F.L., and P.N.T. are principal investigators of the Alzheimer’s Prevention Initiative (API) Autosomal Dominant AD Trial, which is supported by NIA, philanthropy, Genentech, and Roche. E.M.R was supported by grants from the NIA (R01 AG069453, P30 AG072980, RF1AG041705 and R01 AG055444). Y.T.Q. was supported by grants from the National Institute on Aging (R01 AG054671, RF1AG077627, RM1NS132996, U01AG087103), the Alzheimer’s Association, and Massachusetts General Hospital ECOR. Y.T.Q. serves as consultant for Biogen. The remaining authors declare no competing interests.